- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05316870
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation (AMS-AF)
Construction and Evaluation of Standardized Anticoagulant Management Model of Atrial Fibrillation in Primary Medical Institutions Under Hierarchical Diagnosis and Treatment System
Study types and hypotheses: multicenter randomized controlled trials. This study predicts that standardized anticoagulation management of atrial fibrillation in primary health care institutions can reduce the prevalence of atrial fibrillation stroke by 50%.
Formulation and revision of standardized anticoagulation management plan and process for atrial fibrillation in primary health care institutions.
Using the mature anticoagulation management model of atrial fibrillation for reference, based on the clinical data and disease management needs of patients with atrial fibrillation in five community health service centers in Xicheng District of Beijing. To formulate the anticoagulation management plan and process of atrial fibrillation suitable for grass-roots medical institutions. After the completion of the first draft of anticoagulation management plan and process, two rounds of multi-disciplinary experts were organized to demonstrate the feasibility and scientific nature of the first draft. Finally, based on the practice and effect evaluation of clinical application management, the scheme is revised and improved.
- To evaluate the feasibility and clinical application effect of standardized anticoagulation management scheme and process for atrial fibrillation.
First of all, the baseline clinical database of patients with multicenter atrial fibrillation was established; secondly, patients with atrial fibrillation who met the entry criteria were randomly included in the trial group or control group and followed up for two years. The anticoagulation treatment rate, the incidence of bleeding and thromboembolic events, anticoagulation compliance rate and knowledge awareness rate of atrial fibrillation in the two groups were compared, and the effect of standardized anticoagulation management of atrial fibrillation in primary medical institutions was evaluated.
Study Overview
Status
Conditions
Detailed Description
To organize experts to formulate a standardized anticoagulation management plan and process for atrial fibrillation in grass-roots medical institutions
- Write the first draft of "standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions" By searching the anticoagulation management guidelines and expert consensus of atrial fibrillation at home and abroad, do a comparative study, determine the main points of anticoagulation management; analyzing the baseline clinical database of patients with multicenter atrial fibrillation, combined with quantitative and qualitative research, to explore the anticoagulation management needs of patients with atrial fibrillation. Based on the above results, the first draft of standardized anticoagulation management plan and process of atrial fibrillation in grass-roots medical institutions was written.
- Organize expert group interviews. A multidisciplinary expert group was identified, including cardiology, neurology, general medicine, nursing and pharmacy, with 1 or 2 middle-level and above professionals selected in each discipline. Design the interview outline, according to the interview outline, a senior general practitioner encourages and guides the team members to express their own views on the subject. The main contents include: how scientific is this anticoagulation management scheme? What is the value of clinical application? What are the difficulties in the implementation process? What are the contents that need to be further improved?
- Revision and improvement of "standardized anticoagulation management scheme and process for atrial fibrillation in primary medical institutions" According to the results of the expert group interview, revise and further improve the "standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions" to generate the final intervention plan.
To evaluate the clinical effect of standardized anticoagulation management scheme and process for atrial fibrillation.
Observation indicators Main outcome measures: the rate of anticoagulant therapy, the rate of reaching the standard of INR, the incidence of bleeding and thromboembolic events at 3 months, 6 months, 9 months, 12 months, 18 months and 24 months.
Secondary indicators: anticoagulant compliance rate and knowledge awareness rate of atrial fibrillation at 6 months, 12 months and 18 months. Blood routine: hemoglobin, platelet; biochemistry: glutamic pyruvic transaminase, glutamic oxaloacetic transaminase, serum creatinine, urea nitrogen, glomerular filtration rate; electrocardiogram / dynamic electrocardiogram, echocardiography.
- Follow-up plan Patients' symptoms and signs, diet and exercise in the process of anticoagulation management were followed up once a month, and when unmanageable new symptoms or drug side effects appeared, they were referred to secondary or tertiary hospitals for treatment in time; a regular comprehensive physical examination was arranged once a year, including blood routine, biochemical, ECG / dynamic electrocardiogram, echocardiography, etc., and the follow-up period was 2 years.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: lan Ding, Bachelor
- Phone Number: 0086-68056002 0086-13621031422
- Email: ytzxkyb@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 0086
- Recruiting
- Yuetan Community Health Service Center Fu Xing Hospital, Capital Medical University
-
Contact:
- xia J Wang, Master
- Phone Number: 0086-68017528 0086-18800159266
- Email: 1457200352@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old, regardless of sex.
- It is consistent with the diagnostic basis of atrial fibrillation in "Atrial Fibrillation: current Cognition and treatment recommendations-2018".
- Receive oral anticoagulant therapy, such as warfarin or NOACs, as needed.
- There is a contracted family doctor (if not, they can be included in the study after guiding them to sign up for a family doctor).
- Have certain reading comprehension ability, be able to follow up regularly, have good compliance, and select the residents living in the vicinity.
- Volunteer to participate in this clinical study and sign a written informed consent form
Exclusion Criteria:
- Other diseases requiring anticoagulant therapy, such as pulmonary embolism, were included in the group.
- Suffer from severe mental illness or serious diseases that affect their survival, such as AIDS.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
The standardized anticoagulation management program of atrial fibrillation in primary medical institutions was implemented for the patients with atrial fibrillation in the intervention group.
|
Compared with the current anticoagulation management service, we pay more attention to early initiation of anticoagulant therapy and long-term follow-up management.
|
Other: Control group
The current general practitioner management mode was continued for the patients with atrial fibrillation in the control group.
|
The current general practitioner anticoagulation management model was continued in the control group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anticoagulant treatment rate, %
Time Frame: Change from Baseline Anticoagulant treatment rate at 24 months
|
Anticoagulant therapy rate (%) = number of people actually receiving anticoagulant therapy / number of people who should receive anticoagulant therapy x 100%anticoagulant therapy / the total number of people who should receive anticoagulant therapy x 100%.
|
Change from Baseline Anticoagulant treatment rate at 24 months
|
Incidence of bleeding and thromboembolic events
Time Frame: Change from Baseline bleeding and thromboembolic events rate at 24 months
|
Incidence of thromboembolic events / anticoagulation related bleeding events (%) = number of thromboembolic events / anticoagulation related bleeding events in a certain period / number of people observed in the same period x 100% (unit: person year)
|
Change from Baseline bleeding and thromboembolic events rate at 24 months
|
INR compliance rate
Time Frame: Change from 12 months INR compliance rate at 24 months
|
INR compliance rate (%) = the number of INR compliance (2.0 / 3.0) / the total number of INR monitored in the same period × 100%
|
Change from 12 months INR compliance rate at 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anticoagulant compliance rate
Time Frame: Change from 12 months INR compliance rate at 24 months
|
Using the Chinese revised version of Morisky Drug Compliance scale
|
Change from 12 months INR compliance rate at 24 months
|
Knowledge awareness rate of atrial fibrillation
Time Frame: Change from 12 months INR compliance rate at 24 months
|
Awareness rate = the number of correct questions answered by the respondents / the total number of questions answered by the respondents x 100%.
|
Change from 12 months INR compliance rate at 24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Xia J Wang, Master, FuXing Hospital, Capital Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CFH 2020-4-7025
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions
-
Instituto Nacional de Perinatologia Isidro Espinosa...University of Pennsylvania; Bill and Melinda Gates FoundationTerminatedPre-EclampsiaUnited States, Mexico
-
Cocco, Giuseppe, M.D.Cardiology Office, Rheinfelden, SwitzerlandCompletedHeart Failure | Atrial FibrillationSwitzerland
-
Norwegian Institute of Public HealthUniversity of Oslo; Oslo University Hospital; Oslo MunicipalityActive, not recruitingHip Fractures | Fall Injury